Merck (MRK) Goodwill & Intangibles (2009 - 2026)
Merck (MRK) reported Goodwill & Intangibles of $47.3 billion for Q1 2026, up 26.4% year-over-year from $37.4 billion in Q1 2025, and down 1.94% quarter-over-quarter from $48.3 billion in Q4 2025.
Merck (MRK) Goodwill & Intangibles (2009 - 2026) Analysis & Trends
Merck (MRK) has 18 years of Goodwill & Intangibles data on file, last reported at $47.3 billion in Q1 2026.
- Goodwill & Intangibles for Q1 2026 came in at $47.3 billion, up 26.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $47.3 billion (up 26.4% YoY), and the FY2025 annual result was $48.3 billion, up 26.87% from the prior year.
- Goodwill & Intangibles slipped to $47.3 billion in Q1 2026 per MRK's latest filing, from $48.3 billion in the prior quarter.
- Over five years, Goodwill & Intangibles peaked at $48.3 billion in Q4 2025 and troughed at $36.8 billion in Q2 2025.
- A 5-year average of $40.8 billion and a median of $40.4 billion in 2023 frame the typical range for Goodwill & Intangibles.
- The sharpest annual moves came in 2022 and 2023: Goodwill & Intangibles soared 34.51% in 2022, then decreased 7.26% in 2023.
- A 5-year view of Goodwill & Intangibles shows it stood at $41.5 billion in 2022, then declined by 5.46% to $39.2 billion in 2023, then decreased by 2.98% to $38.0 billion in 2024, then rose by 26.87% to $48.3 billion in 2025, then dropped by 1.94% to $47.3 billion in 2026.
- Business Quant data shows MRK's Goodwill & Intangibles at $47.3 billion in Q1 2026, $48.3 billion in Q4 2025, and $36.9 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 47.33 Bn |
| Dec 31, 2025 | 48.26 Bn |
| Sep 30, 2025 | 36.90 Bn |
| Jun 30, 2025 | 36.78 Bn |
| Mar 31, 2025 | 37.44 Bn |
| Dec 31, 2024 | 38.04 Bn |
| Sep 30, 2024 | 38.71 Bn |
| Jun 30, 2024 | 38.15 Bn |
| Mar 31, 2024 | 38.75 Bn |
| Dec 31, 2023 | 39.21 Bn |
| Sep 30, 2023 | 40.38 Bn |
| Jun 30, 2023 | 40.86 Bn |
| Mar 31, 2023 | 41.07 Bn |
| Dec 31, 2022 | 41.47 Bn |
| Sep 30, 2022 | 42.53 Bn |
| Jun 30, 2022 | 43.71 Bn |
| Mar 31, 2022 | 44.28 Bn |
| Dec 31, 2021 | 44.20 Bn |
| Sep 30, 2021 | 32.25 Bn |
| Jun 30, 2021 | 32.50 Bn |